| 1. |
- Ly, Helena-Jamin, et al.
(författare)
-
Comparison of two prediction models in a clinical setting to predict growth in prepubertal children on recombinant growth hormone
- 2023
-
Ingår i: Growth Hormone & Igf Research. - : Elsevier BV. - 1096-6374. ; 68
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Prediction models that calculate the growth response in children on recombinant growth hormone (GH) have shown to be helpful tools in deciding who should start treatment, as identifying GH deficiency can be a challenge. The aim of the study is to compare two prediction models; the KIGS (Pfizer International Growth Study) prediction models which are more accessible and the Gothenburg model which has previously been clinically validated. Design: All prepubertal patients who commenced GH treatment at Queen Silvia Children's Hospital in Gothenburg during a 13-year-period were candidates for the study. Children were excluded if suspected syndrome, malignant disease, chronic disease, or poor adherence to treatment were found. The KIGS model and the Gothenburg model were used to make predictions. Data was obtained from medical charts for the period from birth to the end of the first year of treatment. The predicted height outcome was compared against observed.Results: The study included 123 prepubertal children (76 males). The average age at treatment start and standard deviation (SD) was 5.7 (1.8) years. Correlation analyses were performed between predicted growth by both the Gothenburg and KIGS models versus the first year observed growth response showing strong correlations of r = 0.990 and r = 0.991 respectively with studentized residuals of 0.10 (0.81) for the Gothenburg model and 0.03 (0.96) for the KIGS model.Conclusion: We found that both the Gothenburg model and the KIGS model are equivalent when applying to our clinical cohort. Both models are very precise, hence it is encouraged to use either based on accessibility for the clinic.
|
|
| 2. |
- Brue, Thierry, et al.
(författare)
-
Diabetes in patients with acromegaly treated with pegvisomant : observations from acrostudy
- 2019
-
Ingår i: Endocrine. - : SPRINGER. - 1355-008X .- 1559-0100. ; 63:3, s. 563-572
-
Tidskriftsartikel (refereegranskat)abstract
- PurposeTo explore the effects of pegvisomant (PEGV) on glucose metabolism in patients with acromegaly within ACROSTUDY, an international, observational, prospective safety surveillance study.MethodsPatients were retrospectively divided into two cohorts, with (DM group) or without diabetes mellitus (no-DM). Parameters of glucose metabolism and IGF-I values were analyzed yearly both cross-sectionally for 4 years (yrs) and longitudinally at 1 and 4-5yrs of PEGV treatment.ResultsAmong 1762 patients, 510 (28.9%) had DM before PEGV start. At cross-sectional analyses, in the DM group mean blood glucose was 140.058.7mg/dl at baseline, 116.4 +/- 44.8mg/dl at year 1 and 120.0 +/- 44.3mg/dl at yr 4. Mean HbA1c was 6.6 +/- 1.2 % at yr 1 vs. 7.0 +/- 1.4 % at baseline. HbA1c was above 6.5% in 61.9% at baseline and ranged from 45.4 to 53.8% at subsequent yearly time points. At the 4-yr longitudinal analysis, in the DM group (n=109), mean blood glucose decreased by 20.2mg/dl at yr 4, mean HbA1c was 7.0 +/- 1.5% at baseline vs. 6.8 +/- 1.4%. Patients achieved IGF-I normalization in 52.1% and 57.4% of cases in the DM and no-DM groups, respectively at 1 year. The mean daily PEGV dose (mg/day) was higher in the DM group (18.2 vs. 15.3) while the absolute change of IGF-I values from baseline was similar in both groups. PEGV was well tolerated in both groups without any unexpected AEs.Conclusions p id=Par4 Patients with DM had a moderate decrease in mean fasting glucose values during PEGV treatment.
|
|
| 3. |
- Lindberg, Anders, et al.
(författare)
-
Mechanical performance of polymer powder bed fused objects - FEM simulation and verification
- 2018
-
Ingår i: Additive Manufacturing. - : ELSEVIER SCIENCE BV. - 2214-8604 .- 2214-7810. ; 24, s. 577-586
-
Tidskriftsartikel (refereegranskat)abstract
- Additive manufacturing (3D printing) enables the designing and producing of complex geometries in a layer-by layer approach. The layered structure leads to anisotropic behaviour in the material. To accommodate anisotropic behaviour, geometrical optimization is needed so that the 3D printed object meets the pre-set strength and quality requirements. In this article a material description for polymer powder bed fused also or selective laser sintered (SLS) PA12 (Nylon-12), which is a common 3D printing plastic, was investigated, using the Finite Element Method (FEM). The Material Model parameters were obtained by matching them to the test results of multipurpose test specimens (dumb-bells or dog bones) and the model was then used to simulate/predict the mechanical performance of the SLS printed lower-leg prosthesis components, pylon and support. For verification purposes, two FEM designs for a support were SLS printed together with additional test specimens in order to validate the used Material Model. The SLS printed prosthesis pieces were tested according to ISO 10328 Standard. The FEM simulations, together with the Material Model, was found to give good estimations for the location of a failure and its load. It was also noted that there were significant variations among individual SLS printed test specimens, which impacted on the material parameters and the FEM simulations. Hence, to enable reliable FEM simulations for the designing of 3D printed products, better control of the SLS process with regards to porosity, pore morphology and pore distribution is needed.
|
|
| 4. |
- Duchén, Karel, et al.
(författare)
-
Using a spontaneous profile rather than stimulation test makes the KIGS idiopathic growth hormone deficiency model more accessible for clinicians
- 2017
-
Ingår i: Acta Paediatrica. - : John Wiley & Sons. - 0803-5253 .- 1651-2227. ; 106:9, s. 1481-1486
-
Tidskriftsartikel (refereegranskat)abstract
- Aim: Children treated with a growth hormone (GH) for idiopathic growth hormone deficiency (IGHD) may be monitored with the first-year prediction model from the Pfizer International Growth Database (KIGS) using auxology, age, GH dose and the maximum GH concentration from a stimulation test (GH(max)stim). We tested the hypothesis that using a 12-hour spontaneous profile (GH(max)12h) would be as accurate. Methods: We studied 98 prepubertal Swedish children (78boys) aged2-12 years enrolled in KIGS. The first-year growth was predicted using the GH(max) from the GHprofile and a stimulation test, and both of these were compared separately with the observed growth response. Results: The increased height observed in the first year was 0.74 standard deviation scores (SDS), and the studentised residuals for the predicted and observed growth with GH(max)stim (-0.16 SDS) and GH(max)12h (-0.22) were similar. Individual predictions calculated with stimulated or spontaneous GH(max) showed a significant correlation (r = 0.80). Conclusion: We validated the KIGS IGHD prediction model and found that the stimulated GH(max) peak can be reliably replaced by the GH(max) 12h with similar accuracy. This makes the model more accessible for clinicians, who can then provide realistic expectations for the growth response during the first year of treatment.
|
|
| 5. |
|
|
| 6. |
- van Dijken, Jan W V, et al.
(författare)
-
A 15-year randomized controlled study of a reduced shrinkage stress resin composite
- 2015
-
Ingår i: Dental Materials. - : Elsevier BV. - 0109-5641 .- 1879-0097. ; 31:9, s. 1150-1158
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVES: The aim of this randomized controlled study was to evaluate the long term effectiveness of a reduced shrinkage stress resin composite in Class II restorations. The material was compared intra-individually with a microhybrid resin composite.MATERIALS AND METHODS: Each of 50 patients with at least one pair of two similar sized Class II cavities participated (22 female, 28 male, mean age 43 years, range 18-64). Each participant received in each pair, in a randomized way, one Class II restoration performed with a reduced shrinkage stress resin composite (InTen-S) and the other restoration with a microhybrid resin composite restoration (Point 4). Both restorations were placed with an etch-and-rinse bonding system and an oblique layering technique. A total of 106 restorations, 33 premolar and 73 molars, were placed. The restorations were evaluated blindly each year using modified USPHS criteria. The overall performance of the experimental restorations was tested after intra-individual comparison using the Friedmańs two-way analysis of variance test. The hypothesis was rejected at the 5% level.RESULTS: At 15 years, 91 restorations were evaluated. The drop out frequency was 15 restorations (5 male, 3 female participants; 2 premolar and 13 molar restorations). Except for 2 participants, who reported slight symptoms during a few weeks after placement, no post-operative sensitivity was observed at the recalls. The overall success rate at 15 years was 77%. Twenty-one non acceptable restorations were observed during the 15 years follow up, 10 InTen-S (21.7%) and 11 Point 4 (24.4%) restorations (p>0.05). Annual failure rates for the resin composites were 1.5% and 1.6%, respectively. The main reasons for failure were secondary caries (8) and resin composite fracture (7). The differences between premolar vs. molar restorations and between restorations in male vs. female participants were not significant. Significant differences were observed between 2-surface vs. 3-surface restorations.SIGNIFICANCE: During the 15-year follow up, the reduced shrinkage stress resin composite showed a good clinical durability in Class II cavities, but not significantly better than the control microhybrid resin composite. Secondary caries and material fracture were the main reasons of failure.
|
|
| 7. |
- Reinehr, Thomas, et al.
(författare)
-
Is growth hormone treatment in children associated with weight gain? : Longitudinal analysis of KIGS data
- 2014
-
Ingår i: Clinical Endocrinology. - : Wiley. - 0300-0664 .- 1365-2265. ; 81:5, s. 721-726
-
Tidskriftsartikel (refereegranskat)abstract
- ObjectiveGrowth hormone (GH) increases lean body mass and reduces fat mass. However, the long-term changes in weight status during growth hormone treatment, according to age and weight status at onset of treatment, have not previously been reported in large data sets. MethodsChanges in BMI-SDS between starting GH treatment and attaining near adult height (NAH) were analysed in 2643 children with idiopathic GH deficiency (IGHD), 281 children small for gestational age (SGA), 1661 girls with Turner syndrome (TS), and 142 children with Prader-Willi syndrome (PWS) in the KIGS database. ResultsBMI-SDS increased significantly between onset of GH treatment and NAH (IGHD:+029, SGA:+069, TS:+048) except in PWS (-002). These increases were greater in children with younger age at onset of GH treatment (significant in all indications) and with lower doses of GH treatment (significant in IGHD & TS) in multiple linear regression analyses also including gender, duration of GH treatment, BMI-SDS and height-SDS at onset of treatment, and birth weight-SDS. Obese children at onset of GH treatment decreased their BMI-SDS, while underweight and normal weight children at onset of GH treatment increased their BMI-SDS independently of GH treatment indication. ConclusionsLong-term GH treatment was associated with changes in weight status, which were beneficial for underweight and obese children independent of the indication for GH. However, the increase in BMI-SDS in normal weight children treated with GH needs to be investigated in future prospective longitudinal studies to analyse whether this represents an increase of fat mass, lean body mass or both.
|
|
| 8. |
- Persson, Malin, 1983-, et al.
(författare)
-
In Vitro Motility Assay Studies at Low [MgATP] - Evidence For Inter-Head Cooperativity in Fast Skeletal Myosin II
- 2012
-
Ingår i: Biophysical Journal. - : Biophysical Society. - 0006-3495 .- 1542-0086. ; 102:3 Suppl. 1, s. 146A-146A
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The idea that fast skeletal myosin II exhibits processivity with sequential actions of the two myosin heads during muscle contraction has long been a topic of discussion but with appreciable difficulties to obtain conclusive experimental results. The difficulties may be related to a limited processivity (few sequential head actions) that is of greatest importance at low velocity (e.g. high resistive load), difficult to study accurately in vitro. In order to aid the investigations we here make use of recent evidence that the bipyridine drug amrinone inhibits the strain-dependent ADP-release step of myosin II with expected enhancement of processivity (Albet-Torres et al., J Biol Chem., 2009); Månsson, Biophys J., 2010). For accurate velocity measurements, the recombinant expressed capping protein CapZ (Soeno et. al., J Muscle Res Cell Motil., 1998) was fluorescence labeled. Nanometer tracking was achieved by two-dimensional Gaussian fits to single molecule fluorescence intensity profiles representing CapZ attached to the trailing actin filament end. Importantly, the heavy meromyosin (HMM) propelled actin filament sliding velocity (1mM MgATP) for CapZ-capped filaments was comparable to that of uncapped filaments at different ionic strengths and HMM surface densities. Studies at low [MgATP] (5-30mM) suggests a non-linearity in the [MgATP]-velocity plot that was enhanced by 1mM amrinone. The result is in contrast to the linearity expected for independent myosin heads and could be interpreted as an apparent velocity dependence of the myosin step length. This is in accordance with the idea of limited processivity of myosin II if it is assumed that a doubled apparent step length corresponds to sequential action of the two heads. Further insight into the mechanism will be obtained using proteolytically prepared one-headed HMM and e.g. studies with external loads on actin.
|
|
| 9. |
|
|
| 10. |
|
|
